<DOC>
	<DOCNO>NCT00437697</DOCNO>
	<brief_summary>Intensive care patient high risk develop deep venous thrombosis pulmonary embolism . Despite anticoagulation heparin 7 % ICU patient suffer serious complication . Optimal regimen prevention VTE establish medical patient know ICU patient . It therefore aim study compare bioavailability low molecular weight heparin ICU patient medical patient . Furthermore , look wether 50 % dose increase result good bioavailability drug .</brief_summary>
	<brief_title>Thromboprophylaxis Critically Ill Patients</brief_title>
	<detailed_description>Background : The optimal dose regimen low molecular weight heparin ( LMWH ) thromboprophylaxis critically ill patient unknown . Objectives : We perform prospective , randomize study determine anti-Xa activity follow subcutaneous administration 5000 IU 7500 IU dalteparin thromboprophylaxis ICU patient compare medical patient receive standard dose 5000 IU . Patients Methods : Twenty-five ICU patient receive 7500 IU ( group 1 ) 29 ICU patient receive 5000 IU dalteparin subcutaneously ( group 2 ) thromboprophylaxis . Twenty-nine medical patient receive 5000 IU dalteparin serve control group ( group 3 ) .</detailed_description>
	<mesh_term>Critical Illness</mesh_term>
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Dalteparin</mesh_term>
	<mesh_term>Heparin , Low-Molecular-Weight</mesh_term>
	<criteria>Requirement prophylactic anticoagulation , patient age Â³19 year , creatinine clearance within normal range , prothrombin time &gt; 30 % thrombocyte count &gt; 100 G/l . Estimated time admission le 24 hour , full anticoagulation , renal failure , history heparininduced thrombocytopenia , hereditary acquire coagulation disorder .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2007</verification_date>
	<keyword>dalteparin , critically ill , thromboprophylaxis</keyword>
</DOC>